LOX and melanoma: dLGG–10, Lipo-DOX–2, and dLGG–10 + Lipo-DOX–2 inhibited the 15-LOX-positive-stained melanoma to 58.7%, 56.9%, and 69.6%, respectively, and 15-LOX-positive-microglia/Mφ to 56.1%, 28.1%, and 45.6%, respectively, compared to the tumor control (Mel-A+/15-LOX+: 96.3%; F4/80+/15-LOX+: 90.3%) (Figure 4e).